Showing 701-720 of 746 for: Cochrane Systematic Reviews > Pharmacotherapeutics 
- Thrombolysis (different doses, routes of administration and agents) for acute ischaemic stroke
Cochrane Systematic Reviews, 31-May-2013
Stroke is a leading cause of death and disability world wide. Thrombolysis with recombinant tissue plasminogen activator (rt-PA) is licensed for treatment of acute ischaemic stroke in the early hours after symptom onset. It has been shown in randomised co
- Thrombolysis for acute ischaemic stroke
Cochrane Systematic Reviews, 29-Jul-2014
Most strokes are due to blockage of an artery in the brain by a blood clot. Prompt treatment with thrombolytic drugs can restore blood flow before major brain damage has occurred and improve recovery after stroke in some people. Thrombolytic drugs, howeve
- Thrombolysis for cerebral vein and dural sinus thrombosis
Cochrane Systematic Reviews, 26-Jan-2004
Treatment of cerebral sinus thrombosis with thrombolytics has been reported in cases with a deteriorating clinical course despite anticoagulant therapy. The rationale of this treatment is to promote rapid recanalisation of the occluded sinus.
- Thrombolytic agents for arterial and venous thromboses in neonates
Cochrane Systematic Reviews, 21-Oct-2008
Clinically symptomatic thromboses are infrequent but serious complications in infants undergoing intensive care. Most are related to central vascular catheters. Symptomatic thrombosis may cause severe morbidity due to irreversible organ damage and also lo
- Thrombolytic strategies versus standard anticoagulation for acute deep vein thrombosis of the lower limb
Cochrane Systematic Reviews, 19-Jan-2021
Standard treatment for deep vein thrombosis (DVT) aims to reduce immediate complications. Use of thrombolytic clot removal strategies (i.e. thrombolysis (clot dissolving drugs), with or without additional endovascular techniques), could reduce the long-te
- Thrombolytic therapy for pulmonary embolism
Cochrane Systematic Reviews, 15-Apr-2021
Thrombolytic therapy is usually reserved for people with clinically serious or massive pulmonary embolism (PE). Evidence suggests that thrombolytic agents may dissolve blood clots more rapidly than heparin and may reduce the death rate associated with PE.
- Thyrotropin‐releasing hormone added to corticosteroids for women at risk of preterm birth for preventing neonatal respiratory disease
Cochrane Systematic Reviews, 21-Nov-2013
Thyrotropin-releasing hormones (TRH) added to prenatal corticosteroids has been suggested as a way to further reduce breathing problems and neonatal lung disease in infants born preterm.
- Tiotropium for stable chronic obstructive pulmonary disease
Cochrane Systematic Reviews, 20-Apr-2005
Tiotropium is a new anticholinergic therapy for chronic obstructive pulmonary disease (COPD) that differs from ipratropium by its functional relative selectivity for muscarinic receptor subtypes and which allows once-per-day dosing.
- Topical agents and dressings for fungating wounds
Cochrane Systematic Reviews, 15-May-2014
Fungating wounds arise from primary, secondary or recurrent malignant disease and are associated with advanced cancer. A small proportion of patients may achieve healing following surgical excision, but treatment is usually palliative. Fungating wound man
- Topical corticosteroids as adjunctive therapy for bacterial keratitis
Cochrane Systematic Reviews, 16-Oct-2014
Bacterial keratitis is a serious ocular infectious disease that can lead to severe visual disability. Risk factors for bacterial corneal infection include contact lens wear, ocular surface disease, corneal trauma, and previous ocular or eyelid surgery. To
- Topical nasal steroids for intermittent and persistent allergic rhinitis in children
Cochrane Systematic Reviews, 24-Jan-2007
Allergic rhinitis is a very common chronic illness affecting 10% to 40% of children worldwide. There has been a significant increase in prevalence among children over the last two decades and this increase has been accompanied by a parallel increase in co
- Topical pimecrolimus for eczema
Cochrane Systematic Reviews, 22-Mar-2009
Pimecrolimus was developed as an alternative to topical corticosteroids for treating eczema (atopic dermatitis) but its efficacy and safety compared with existing treatments remains unclear.
- Traditional corticosteroids for induction of remission in Crohn's disease
Cochrane Systematic Reviews, 28-Feb-2010
Historically, corticosteroids have been the most commonly used class of medication for induction of remission in Crohn's disease (CD). Corticosteroids down regulate production of inflammatory cytokines and interfere with NF-?B production, thereby blunting
- Treatment and prevention of pouchitis after ileal pouch‐anal anastomosis for chronic ulcerative colitis
Cochrane Systematic Reviews, 30-Nov-2019
Pouchitis occurs in approximately 50% of patients following ileal pouch-anal anastomosis (IPAA) for chronic ulcerative colitis (UC).
- Treatment for amphetamine dependence and abuse
Cochrane Systematic Reviews, 15-Apr-2014
Amphetamine use is of concern because it causes a variety of devastating health physical and neurological consequences, including amphetamine-induced mental disorders.
- Treatment for amphetamine psychosis
Cochrane Systematic Reviews, 21-Jan-2009
Chronic amphetamine users may have experience of paranoia and hallucination. It has long been believed that dopamine antagonists, such as chlorpromazine, haloperidol, and thioridazine, are effective for the treatment of amphetamine psychosis.
- Treatment for IgG and IgA paraproteinaemic neuropathy
Cochrane Systematic Reviews, 24-Mar-2015
Paraproteinaemic neuropathy refers to those neuropathies associated with a monoclonal gammopathy or paraprotein. The most common of these present with a chronic, predominantly sensory, symmetrical neuropathy, similar to chronic inflammatory demyelinating
- Treatment for Lambert‐Eaton myasthenic syndrome
Cochrane Systematic Reviews, 16-Feb-2011
Lambert-Eaton myasthenic syndrome (LEMS) is an autoimmune disorder of neuromuscular transmission. Treatments attempt to overcome the harmful autoimmune process, or improve residual neuromuscular transmission
- Treatment for superficial thrombophlebitis of the leg
Cochrane Systematic Reviews, 25-Feb-2018
The optimal treatment of superficial thrombophlebitis (ST) of the legs remains poorly defined. While improving or relieving the local painful symptoms, treatment should aim at preventing venous thromboembolism (VTE), which might complicate the natural his
- Tricyclic and related drugs for nocturnal enuresis in children
Cochrane Systematic Reviews, 20-Jan-2016
Enuresis (bedwetting) affects up to 20% of five year-olds and 2% of adults. Although spontaneous remission often occurs, the social, emotional and psychological costs can be great. Tricyclics have been used to treat enuresis since the 1960s.
